Clinical characteristics, treatment, and management of pembrolizumab induced hemophagocytic lymphohistiocytosis
C Wang, W Sun, Z Li, T Wu, W Fang - Investigational New Drugs, 2023 - Springer
Background Hemophagocytic lymphohistiocytosis (HLH) is a rare and fatal adverse reaction
to pembrolizumab. The clinical characteristics of pembrolizumab induced HLH are unknown …
to pembrolizumab. The clinical characteristics of pembrolizumab induced HLH are unknown …
COVID-19 Outcomes in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review
JI Ruiz, MA Lopez-Olivo, Y Geng… - Journal of …, 2023 - meridian.allenpress.com
ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) can cause inflammatory and
immune-related adverse events (irAEs) that might worsen the course of COVID-19. We …
immune-related adverse events (irAEs) that might worsen the course of COVID-19. We …
Secondary haemophagocytic lymphohistiocytosis: case report
L Ramos-Ruperto - Reactions, 1867 - ncbi.nlm.nih.gov
The man, who had lung adenocarcinoma, had been receiving pembrolizumab [route and
dosage not stated]. He consulted in the emergency department for fever and 1-week of …
dosage not stated]. He consulted in the emergency department for fever and 1-week of …